(Adnkronos) - In questo numero:
Stop 'Far West' probiotici, alla Camera convegno e presentazione Pdl
A Roma il 54° Congresso della Società italiana di Neurologia
Aifa approva rimborsabilità ravulizumab per miastenia gravis
Primo congresso “Vivi Porfiria: conoscenza, condivisione e cura”, sabato 23 novembre a Milano
E ancora
"Prevenzione e vaccini" il focus a Health Innovation Show 2024
Neurologia, assegnato il premio Merck per l’innovazione digitale
Farmaceutica: Italia unicum in Europa, ma serve una strategia Life Sciences
Convegno a Roma per ridare dignità e valore sociale alla professione sanitaria pubblica
‘Recupera e respira’: 73 mila inalatori raccolti in 360 farmacie del progetto di Chiesi Italia e Federfarma e Fvg
Stop 'Far West' probiotici, alla Camera convegno e presentazione Pdl
A Roma il 54° Congresso della Società italiana di Neurologia
Aifa approva rimborsabilità ravulizumab per miastenia gravis
Primo congresso “Vivi Porfiria: conoscenza, condivisione e cura”, sabato 23 novembre a Milano
E ancora
"Prevenzione e vaccini" il focus a Health Innovation Show 2024
Neurologia, assegnato il premio Merck per l’innovazione digitale
Farmaceutica: Italia unicum in Europa, ma serve una strategia Life Sciences
Convegno a Roma per ridare dignità e valore sociale alla professione sanitaria pubblica
‘Recupera e respira’: 73 mila inalatori raccolti in 360 farmacie del progetto di Chiesi Italia e Federfarma e Fvg
Category
🗞
NewsTranscript
00:00In this number, Stop Far West Probiotics, at the Chamber Convention and PDL presentation.
00:17In Rome, the 54th Congress of the Italian Society of Neurology.
00:22AIFA approves the re-wearing of Ravulizumab for myasthenia gravis.
00:28First Congress Vivi Porfiria, knowledge, sharing and care, Saturday, November 23 in Milan.
00:36And again, vaccine prevention, the focus of the Health Innovation Show 2024.
00:42Neurology, awarded the Merck Award for digital innovation.
00:48Pharmaceuticals, Italy unique in Europe, but needs a Life Sciences strategy.
00:55Convention in Rome to restore dignity and social value to the public health profession.
01:01Recupera e Respera, 73,000 inhalers collected in 360 pharmacies of the Chiesi Italia, Federpharma and Fivigy project.
01:16There are very few medical sectors that are now explored, studied and described with so much precision
01:22as the one related to the intestinal microbiota and its correlations with the maintenance of the state of health of man.
01:28It is enough to consider that from January 1 to October 1, 2024, more than 3,000 scientific works have been produced.
01:34An ecosystem of complex microorganisms, the microbiota, able to influence the emergence and evolution of many diseases,
01:40but also to intervene in the virtuous dynamics of active aging, in contrast to the colonization by pathogens,
01:46in the mechanisms of action of drugs and in the therapeutic success of various care protocols.
01:50Thus, the immunologist Mauro Minelli, a teacher of dietetics and nutrition at the University of L'UM in Bari,
01:56among the specialists who participated in the Convention Economy and Science of the Microbiome,
02:00Management of Innovation in Biomedicine, took place in Rome in the hall of the Refectory of the Library Nildeiotti of the Chamber of Deputies.
02:07A scientific event promoted by the Vice President of the Chamber, Giorgio Mule,
02:11under the auspices of the Foundation for Personalized Medicine and the Order of Surgeons and Odontologists of the Province of Rome.
02:17Health or disease that do not only interest the intestinal environment, if we refer to the intestinal microbiota,
02:24but this innumerable quantity of cells also contributes a lot to the health of extra-intestinal structures.
02:32We are talking about the cardiovascular system, we are talking about the neurological system, we are talking about the immune system.
02:38So what to do to cure this world when it should be altered?
02:44In the meantime, the only remedy we have is to know it in detail and then impose on that knowledge any probiotic therapies.
02:54The great chapter of probiotics opens, a chapter that would need a little more attention
03:02is the topic that was discussed in the scientific seminar of the Chamber of Deputies,
03:07where a bill was presented that will focus exactly on the methods of study, analysis and experimentation of probiotic therapies.
03:17Dysbiosis, this is the scientific term to indicate an alteration in the composition of the microbiota,
03:22in fact varies from person to person and, as the experts emphasize, it is not correct to treat them all with the same probiotics.
03:28It would be enough to keep in mind that the bacterial composition of the intestinal microbiota of European subjects
03:34is completely different from the bacterial composition of the flora that interests, for example, healthy American adults.
03:43And if this is true for different geographical areas, in the same geographical areas it varies for different subjects,
03:51different by sex, by age, by pathological conditions.
03:55Therefore, studying the microbiota means being able to have the actual possibility,
04:00not to do such a knowledgeable and sufficient examination,
04:03but to do an examination that can allow,
04:06at the same level as what is done for antibiotic therapies,
04:10by preliminarily verifying an antibiogram,
04:13to have a precise picture of the bacterial composition to impose a probiotic therapy of precision.
04:19For this reason, today we have presented the model of the probiogram
04:24that also involves methods of artificial intelligence.
04:27And how does this probiogram come about?
04:30Let's say that it is not possible to study the bacteria of the intestinal microbiota with a microbiological examination,
04:35because they are so numerous that it would not be absolutely possible.
04:40Therefore, this obstacle has been overcome through investigations
04:44that practically use genetic evaluations.
04:49That is, today it is possible to study the entire composition of the bacterial DNA
04:55and thanks to these analyses of microbial genomics and then subsequent applications of bioinformatics,
05:02it is possible to have an exact, precise spectrum of what is the individual characterization of the microbiota.
05:09Now, it often happens, however, that this study,
05:12which involves a lot of scientific know-how behind it,
05:17remains almost a curiosity that a person wants to complete
05:21to verify their state of eubiosis or dysbiosis.
05:26It makes sense, however, if on that examination,
05:29which can even be used for metabolomic investigations,
05:33that is, I study the genetics of bacteria,
05:35I do not know what functions they have,
05:37to know the functions they have,
05:39it is possible then to carry out a further examination
05:42that makes me understand the metabolites that those bacteria produce
05:46and therefore the damage or benefit that those bacteria bring me.
05:49Well, knowing this information,
05:52it is possible that I can apply a correct correction therapy
05:56in case I need it.
05:59What are the main themes?
06:03The main themes that revolve around brain health,
06:06from diseases related to inflammation and stroke,
06:09and the new diagnostic horizons offered by biomarkers
06:12that allow the early recognition of many diseases,
06:15especially those neurodegenerative,
06:17were at the center of the 54th Congress of the Italian Society of Neurology in Rome,
06:22at the Centro Congressi La Nuvola.
06:24The president of the scientific society
06:26tracks a balance of the 2024 edition of the Congress.
06:29This was perhaps the most popular national convention,
06:34we had more than 3,000 appearances
06:37and 2,500 members who were here for three days.
06:42I must say, it was perhaps the most exciting edition said of all,
06:46it may also be because this is a great place,
06:49it may also be because Rome is Rome,
06:51but of course we had a great success,
06:54especially in the satisfaction of those who came here,
06:58but also the quality of the speakers,
07:00we made a very strong choice,
07:02also very characterized on topics that could interest the general public,
07:08but bringing here experts, even international.
07:11The progress of genetic engineering
07:13is making a splash in the treatment of Parkinson's disease.
07:17There are therapies for Parkinson's disease,
07:21and perhaps when we talk about resolution therapies,
07:25there are expectations that perhaps are not easily resolved at the moment,
07:32but keep in mind that there are some forms of Parkinson's disease
07:35due to genetic diseases or genetic alterations.
07:38On this, even Aguzzi's report indicates
07:41that genetic engineering is making huge strides
07:45and we will probably have personalized therapies
07:48according to the genetic predisposition.
07:50For Alzheimer's disease, there are drugs that control the symptoms,
07:54but it is necessary to take further steps in the research.
07:57We need drugs that can prevent the disease,
08:01slow down the disease and perhaps stop the disease.
08:04I would say that here the light at the end of the tunnel is getting a little clearer,
08:09I am not among those who believe that you have to go too fast,
08:12if EMA will try, this will dramatically change our system,
08:17but in addition to the drugs that are currently being discussed in EMA,
08:20there are many others in development.
08:22So I believe that even for Alzheimer's disease,
08:25without rushing, but the future of the next few years is certainly satisfactory.
08:36AstraZeneca, together with Alexion AstraZeneca Rare Disease,
08:40has announced that the Italian Pharmaceutical Agency
08:43has approved the reimbursement of Ravulizumab,
08:46inhibitor of the long-term action complement C5,
08:49as an additional therapy to the standard therapy
08:52for treating adult patients affected by generalized serious myasthenia.
08:57The topic was discussed at the meeting
08:59of a new management of generalized serious myasthenia,
09:02approved by Ravulizumab, for the treatment of adult patients
09:06and held at Terrazza Gym in Milan.
09:08Ravulizumab is a humanized monoclonal antibody
09:12specific for the complement C5 fragment.
09:15The complement has a fundamental role in serious myasthenia,
09:18as it is activated by specific autoantibodies for the receptor of acetylcholine
09:23and the activation of the complement has the consequences of thetheria,
09:26as it alters the morphology of neuromuscular junction,
09:30thus preventing the transmission of the impulse between the nerve and the muscle,
09:34causing the symptoms of the pathology.
09:36Generalized serious myasthenia
09:38is a pathology with a strong impact on patients
09:41and this new therapy can significantly improve the quality of life.
09:45The arrival of this new therapy is extremely important,
09:50the indications for use are those as an addition to the standard therapy,
09:56but what happens is that it quickly improves the symptoms,
10:03because refractory patients are the first to be involved
10:12and above all it allows to significantly reduce conventional therapies,
10:21which are those that are more prone to side effects,
10:26in particular steroid therapy.
10:29Once again it is confirmed the commitment of Alexion, AstraZeneca Rare Disease,
10:33in dealing with rare diseases,
10:35combining research, innovation and care for patients.
10:38We believe that it is essential not only to deal with research and development of innovative drugs,
10:45but also to collaborate with the whole ecosystem that rotates and is part of the world of rare diseases
10:52to try to improve the daily life of these patients.
10:55This is because the path of the rare patient is a path of obstacles,
10:59starting with diagnosis, then of course the possibility of having an effective therapy available,
11:04and then also in living what is the daily life.
11:09In doing this, we think it is essential to work in concert with the association of patients,
11:17with the scientific community and also with the institutions
11:20to really understand what the needs are and to create solutions together,
11:25because only in this way can we really be able to create something useful.
11:30And this is our way of working, what we do every day.
11:39Creating information so as not to leave anyone in the shadows.
11:41And this is the goal of the first national congress
11:43VIVI PORFIDIA, knowledge, sharing and care,
11:47which will take place on Saturday, November 23 in Milan at the Testori Auditorium of the Palazzo della Regione Lombardia,
11:52from 10 to 16.
11:53Born from the commitment of 6 patients affected by one of the 8 forms of porphyria,
11:56the association wants to make these rare diseases better known,
11:59in order to facilitate diagnosis and avoid suffering and humiliation to the patients.
12:03From the knowledge, in fact, read in the program of the event,
12:06originate networks that strengthen the rights of patients.
12:09And to pursue this intention, the first national day of the patient affected by porphyria,
12:14is the genius group of rare metabolic diseases,
12:16classified into two groups, hepatic and erythropoietic,
12:19depending on the main location of the metabolic anomaly that causes it.
12:23They are in fact due to the deficit of one of the enzymes of the biosynthesis of the heme,
12:27a chemical complex made up of a family of compounds called porphyrins,
12:30which, when accumulated, can cause various symptoms,
12:33from neurovisceral attacks to cutaneous lesions, also painful due to photosensitivity,
12:37or the combination of these two types of manifestations.
12:40Clinical signs usually appear in adulthood, but in some cases even in childhood,
12:44and can have serious repercussions on the quality of life of those who suffer from them.
12:48Many, therefore, are the issues that will be addressed with the experts during the Congress,
12:51from diagnosis to clinical and psychological management,
12:54fundamental for a correct path of treatment,
12:57up to access to health services,
12:59a way to allow the sharing of best practices
13:01and the update on recent progress in the treatment of such pathologies.
13:05And all this to improve the quality of life of them and their families
13:08and develop initiatives for the continuous support of people affected by porphyria.
13:12On stage, the top experts in medicine, biologists and psychologists,
13:19but above all, patients will come up to share what it really means to live with porphyria.
13:25The event organized by us, by the Vivi Porphyria team,
13:29we are a young association born in 2023 with the educational purpose.
13:34The day will be dedicated to sharing the experiences of patients
13:40and to bring awareness and knowledge to this group of rare diseases.
13:50The Health Innovation Show 2024 convened in Rome,
13:54a moment of discussion on the most innovative health issues
13:57that catalyze the political commitment at both central and local level.
14:02Within it, the focus was kept by the title Vaccine Prevention.
14:06According to the World Health Organization,
14:09one of the strategies to be used in contrast to antibiotic resistance are vaccinations.
14:15This is because, obviously, by vaccinating us and not having respiratory infections,
14:21which are the ones that we most frequently encounter
14:25and that often lead to the use of antibiotics in an erroneous way,
14:30because they are, in most cases, viral infections,
14:33well, the vaccination, preventing these cases,
14:36strongly reduces the inappropriate use of antibiotics.
14:42In Lazio, initiatives dedicated to awareness and information on the subject of vaccinations are growing.
14:48We have implemented three actions.
14:50The first is to study, of course, the phenomenon
14:53and therefore a task force and the creation of a computer platform
14:59that will then serve to help us in the orientation
15:02and in the statification of the needs of the population.
15:05The second is that we have started to open vaccination ambulatories
15:09throughout the hospital structure
15:11and with this we go to vaccinate our fragile, our chronic patients directly.
15:17But the third is, instead, the use, through a multi-screening camper,
15:22which also, let's say, runs in 22 different positions,
15:28is bringing not only prevention on primary screenings,
15:32mammogram, cervix and colon,
15:35but also vaccination and message, dissemination and information
15:40on vaccines coherently adopted by pediatricians,
15:45but above all on HPV to eradicate carcinoma of the uterine cervix
15:50and on Zoster, since the demographic increase of our elderly
15:55also imposes prevention of this type.
15:57At FOCUS we talked about new technological and digital solutions,
16:01new methods of analysis and management
16:03that know how to contribute to economic sustainability
16:06and efficiency of prevention and intervention.
16:08We know very well that vaccination represents the most cost-effective intervention
16:14in terms of public health.
16:15From this point of view, the National Health Fund
16:18dedicates 5% to prevention, which can generate a very important value.
16:24Estimates of literature tell us that for every euro invested in vaccination
16:28we have a return of 19 euros for everything related to avoided recoveries,
16:33but also welfare in social terms,
16:35because vaccinations are precisely the paradigm
16:37of how the intervention in prevention
16:39is not only reverberated within the National Health Service,
16:43but in a much broader perspective throughout society.
16:45And we have seen during the pandemic
16:47what it means to block an entire society due to an infectious disease.
16:55Early identification of the silent symptoms of multiple sclerosis
16:59thanks to the analysis of the patient's behavior
17:02when using the smartphone through artificial intelligence.
17:05This is the goal of the winning project of the sixth edition
17:09of the Digital Innovation Award in Neurology,
17:11promoted by Merck with the sponsorship of the Italian Society of Neurology.
17:15In recognition,
17:17conferred in the context of the 54th Congress of the Scientific Society,
17:21Professor Pasquale Arpaia,
17:23Director of the project at the Federico II University of Naples.
17:27Instead of using dedicated apps that bore the patient,
17:31from the daily interaction with the apps already native to the cell phone,
17:36sending a WhatsApp message,
17:40writing messages,
17:42then the patient who has these silent symptoms
17:46obviously experiences difficulties,
17:49small hiccups, delays,
17:51difficulty in typing.
17:53Artificial intelligence inside the cell phone
17:56realizes this difficulty
18:00and provides useful support to the doctor.
18:05So, as always,
18:07in our actions of technology, innovation and medicine,
18:10the patient in the first place and then the doctor next to him.
18:14Technology at the service of man.
18:17Committed for more than 30 years in research and development of transformative drugs for patients,
18:22today Merck also works to create innovative technological solutions
18:26that can help doctors understand daily the evolution of the disease of their patients.
18:31For this reason, this year we have reached the 6th edition
18:35of the Digital Innovation Award of Merck
18:39aimed at finding projects that can solve this problem
18:47of being able to monitor patients constantly.
18:50We know that the disease with multiple sclerosis
18:54is a disease that evolves mainly with the so-called silent symptoms,
18:59but in reality very often these silent symptoms
19:02are not taken from the clinic because they are subtle
19:05and there is no adequate technology to be able to monitor these aspects.
19:10Thanks to today's technological and digital innovations,
19:15thanks to artificial intelligence,
19:17we can really provide the clinic with information
19:21that can have an immediate mirror of what is the state of evolution of a patient's disease.
19:27To slow down the progression of multiple sclerosis,
19:29Merck has developed Cladribina,
19:31with high efficiency, ease of supply and optimal safety profile.
19:36Cladribina has a very interesting and innovative mechanism
19:40that we define as immune-replacing.
19:42What does immune-replacing mean?
19:45It means that the drug is able to deplete,
19:48therefore to kill, lymphocytes B and lymphocytes T,
19:51which are the ones that subsequently attack myelin
19:54and therefore determine the tissue damage and the progression of disability.
19:57After the intake of Cladribina,
19:59these lymphocytes B and these lymphocytes T tend to be significantly reduced
20:06and the myeloid begins to rebuild new lymphocytes B and T
20:11that in theory have no memory against myelin
20:13and therefore we are able, over time,
20:15to control the aggression of these cells on the myelin
20:20and to control the progression of disability.
20:28With a production that in 2023
20:30exceeded for the first time 50 billion euros,
20:333.6 billion investments in innovation
20:36and a growing number of patents,
20:38the Italian pharmaceutical sector represents a unique one in Europe
20:42and has a key role for our country.
20:45Italian pharmaceutical excellence
20:47can be a powerful magnet capable of attracting investments
20:50and a strong stimulus for Italian competitiveness in Europe and the world.
20:55We talked about it in Rome,
20:56during the meeting
20:57The Value of the Pharmaceutical Sector in the Country System,
21:00an Italian life science strategy
21:03promoted by Sanofi Italia in Rome
21:05at the Centro Studi Americani
21:07where institutions, experts and companies
21:09met to build together
21:12a life science development strategy,
21:15a strategic partnership for the economy,
21:17the occupation and the development of innovation
21:19and the growth of our country.
21:21Today we wanted to promote a meeting
21:23dedicated to the strategic value
21:26that the pharmaceutical sector brings to the country system
21:29with a deepening,
21:31thanks also to the collaboration with the Institute of Research VIFOR,
21:34precisely on the data that Sanofi brings,
21:38the impact that Sanofi brings to the country.
21:40In particular, significant data emerged,
21:441.4 billion in terms of contribution to the PIL,
21:49but also in terms of the value
21:52that each place of work in Sanofi generates
21:57in the country system,
21:59with a multiplier of more than 5.
22:02Also important data on the R&D intensity of 3%.
22:09Italy will play a fundamental role
22:12also in clinical research.
22:14All this is important,
22:16but what we want to do today
22:18is to launch an appeal,
22:20an appeal to the country
22:23to adopt a comprehensive life science strategy
22:30of various aspects,
22:32where precisely the life science sector
22:35is put at the center of the development of this country.
22:38According to the latest analysis
22:40of the Technology Forum Life Science
22:42promoted by The European House Ambrosetti,
22:45Italy ranks among the countries
22:47with medium-high innovation,
22:49but remains far from the top performers.
22:51Today Italy positions itself
22:53for foreign direct investments
22:56behind Germany, France and Spain.
22:59In Europe, we have seen over the years
23:01that other countries have equipped themselves
23:04with a real vision and strategy of life science,
23:07a structured plan of interventions
23:11and an integrated policy
23:13that can also involve other ministries.
23:15So let's also think about research policies,
23:17health policies,
23:19which are fundamental in a system
23:21in which this sector wants to be valued.
23:23A sector that is important,
23:25that gives a contribution
23:27of more than 2% of GDP to our country.
23:30And if we only look at the share
23:32of multinationals in foreign capital
23:34that join the APG and Unifarma,
23:36we are talking about about 20 billion euros
23:39of direct, indirect and inductive contribution,
23:42more than 1% of GDP.
23:44A value that can certainly increase,
23:46which can therefore help to accelerate
23:48the recovery and economic growth
23:50that our country needs.
23:55A meeting was held at the Queen's Room
23:57of the House of Representatives,
23:59an agreement organized by the
24:01Reanimatory Anesthesiologists
24:03and the Emergency Emergencies Syndicate
24:05with the need to resuscitate and cure
24:07the public health of our country.
24:09A meeting that was an opportunity
24:11to talk about the Italian public health system
24:13and the value of the health personnel
24:15that guarantees its operation.
24:17Today's event, entitled
24:19The Social Value of Public Employment,
24:21includes the themes on which we thought
24:23to ask for a moment of reflection,
24:25of meeting between the institutions
24:27and the various representatives
24:29of the professional world of public health.
24:31This is to face together
24:33and find synergies in order to
24:35individually solve the problems
24:37that afflict our national health service,
24:39namely public employment and spinal cord.
24:41An initiative that comes at a particular
24:43historical moment for the sector,
24:45which has seen in recent years
24:47the recognition of the work
24:49in the national health system,
24:51making urgent the start of a direct
24:53confrontation between institutions,
24:55representatives of workers,
24:57scientific societies and associations
24:59with the intention of identifying
25:01the reasons why public health
25:03has lost its attractiveness.
25:05As a priority, Minister Schillach
25:07has said,
25:09we are investing money.
25:11In the next three years,
25:13the balance sheet will provide
25:15about 12 billion more
25:17on the national health service.
25:19We certainly know
25:21that we need to do more,
25:23reorganize,
25:25so that the financing
25:27of the national plan of recovery
25:29and resilience, with the creation
25:31finally of the structure
25:33of territorial health,
25:35is part of a reorganization
25:37that, in our opinion,
25:39also takes place at the same time
25:41in search of new funding
25:43and new resources
25:45that can be put
25:47on the national health service.
25:49The Chamber of Deputies
25:51also had the opportunity
25:53to discuss the problems
25:55that affect the system.
25:57A useful time to look for solutions
25:59and proposals for a more sustainable
26:01future, to improve the well-being
26:03and to be able
26:05to realize
26:07are those that give value
26:09to the public-dependent relationship
26:11within the public health service,
26:13which has recently been distorted
26:15by a whole series of atypical relationships,
26:17including the use of
26:19the supply of services
26:21through private parties
26:23to the so-called cooperatives,
26:25which are actually extremely expensive
26:27compared to a relationship
26:29with the quality and safety of care
26:31of the Italian health service.
26:33The Scientific Society of Anesthesia and Reanimation,
26:35Intensive Therapy and Pain
26:37sees as a reference,
26:39as a lighthouse at night,
26:41the possibility of training
26:43for young colleagues
26:45and for younger colleagues
26:47to be a reference also with good clinical practices,
26:49guidelines, what we call
26:51increasing quality
26:53and guaranteeing safety.
26:55More than 350 adherent pharmacies
26:57and more than 73,000 inhalers
26:59and respirators
27:01made and collected
27:03are these data
27:05that photograph the great success
27:07of the Recupera e Respira project,
27:09designed and promoted by Chiesi Italia
27:11and Feder Pharma
27:13with the support of the Friuli-Venezia Giulia region.
27:15The aim of the project,
27:17which was born as a response to the commitment
27:19of Chiesi to reach zero net emissions
27:21of greenhouse gas,
27:23is to improve inhaler disinfection habits
27:25by encouraging patients
27:27not to throw medical devices
27:29in the indifferent collection
27:31but to return them to the pharmacy
27:33for their correct disinfection.
27:35This project is based on the correct disinfection
27:37of all respiratory devices,
27:39once disinfected,
27:41that are used by patients
27:43with respiratory pathologies.
27:45This avoids greenhouse gas emissions
27:47that are represented
27:49by propellant residues
27:51The correct disinfection
27:53occurs through a thermovalorizer
27:55at a temperature of 1,100 degrees,
27:57which, on the other hand,
27:59also produces electrical energy
28:01that is emitted in the region,
28:03in this case Friuli-Venezia Giulia.
28:05The president of Feder Pharma
28:07Friuli-Venezia Giulia explains
28:09how Recupera e Respira
28:11also has an impact on the role of the pharmacist.
28:13This initiative is very interesting
28:15because it opens up a scenario
28:17in which the role of the pharmacist
28:19not only for the pharmacists
28:21but also for the care of patients,
28:23to monitor adherence,
28:25to take care of health
28:27at 360 degrees.
28:29The project promoted by Chiesi Italia
28:31and Feder Pharma
28:33fits perfectly into the strategy
28:35for greater sustainability
28:37adopted by the Friuli-Venezia Giulia region.
28:39This project perfectly integrates
28:41within a long-term vision
28:43that the region has,
28:45because it reuses
28:47the right waste
28:49within a sustainable
28:51and environment-friendly economy,
28:53as the project of recovery
28:55of the inhaler
28:57by the pharmacies
28:59goes in this direction.
29:05This was our latest news.
29:07To contact us, you can write to
29:09salute-adianecronos.com
29:11Thank you for following us
29:13and see you in the next episode.
29:17Thank you for following us
29:19and see you in the next episode.